Harvard College

Dana-Farber-Cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

Novartis Ag

Emory University

Other

University of Pennsylvania

Children's Medical Center Corporation

Beth Israel Deaconess Medical Center, Inc.

Genetics Institute, Inc.

Boston Children's Hospital

Arlene Helen Sharpe

Gordon James Freeman

Gerhard Johann Frey

Hwai Wen Chang

Jennifer Marie Mataraza

Loise M Francisco

Lee M Nadler

Rafi Ahmed

Francescopaolo Borriello

Walter A Blattler

Catherine Anne Sabatos-Peyton

E John Wherry

Daniel Barber

Peter T Sage

David M Dorfman

Vikram R Juneja

Gordon Freeman

Jennifer Brogdon

Glenn Dranoff

Dale T Umetsu

Reshma Singh

Boris Engels

Rosemarie Dekruyff

Vassiliki A Boussiotis

Yanping Xiao

William N Haining

Xia Bu

Nikolaos Patsoukis

Jessica Weaver

Laura Strauss

Jernej Godec

Clive R Wood

Vijay K Kuchroo

Rama Rao Amara

Yvette Latchman

Nelly Malenkovich

Tatyana Chernova

Yang Shi

Irene Chernova

Scott B Lovitch

Janet Buhlman

Didier Mandelbrot

Catherine L Tan

Wanqiang Sheng

Masao Hashimoto

Martin W LaFleur

Hyun T Jin

Sun J Lee

Gordan Freeman

The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.

Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Antibody molecules to PD-1 and uses thereof

Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.

Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof

Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.

Agents that modulate immune cell activation and methods of use thereof

The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).

Regulatory T cell PD-1 modulation for regulating T cell effector immune responses

The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.

Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors

The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses and the use of those methods in the treatment of diseases or conditions such as viral, bacterial, pathogenic, or fungal infections or cancer. Such methods provide for boosting of antibody production through the use of IL-21 to overcome TFR cell suppression of antibody production.

Compositions and methods for modulating an immune response

The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.

Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.

Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators

Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Antibody molecules to PD-L1 and methods of treating cancer

Growing community of inventors

Brookline, MA, United States of America

Arlene Helen Sharpe